Intercept Announces Updated U.S. Prescribing Information for Ocaliva® (obeticholic acid) to Reinforce Appropriate Dosing in PBC Patients with Advanced Cirrhosis
Go back to Intercept Announces Updated U.S. Prescribing Information for Ocaliva® (obeticholic acid) to Reinforce Appropriate Dosing in PBC Patients with Advanced Cirrhosis| INTERCEPT PHARM (NASDAQ: ICPT) | Delayed: 19.00 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $19.00 | 52 Week High | $186.87 | |||
| Open | $213.72 | 52 Week Low | $89.76 | |||
| Day High | $19.00 | P/E | N/A | |||
| Day Low | $19.00 | EPS | $-5.79 | |||
| Volume | 2,412,753 | |||||
